Clinical Trial Update: Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intracoronary darbepoetin-alpha to reduce infarct size and post-infarct remodeling in myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Darbepoetin-alpha (darbepoetin alfa)

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Myocardial Infarction | Phase 2 | Status: COMPLETED